

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: NEXALIS THERAPEUTICS LTD
ACN: 611 845 820

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sean Williams
Date of last notice	17 February 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	TG Advisory Pty Ltd <Williams Glenair Family A/C> <i>Mr Williams is a Director of TG Advisory Pty Ltd and a beneficiary of the Williams Glenair Family A/C</i> Mr Sean Williams + Mrs Catherine Williams <S & C Williams Super A/C> <i>Mr Williams is a beneficiary of the S & C Williams Super A/C</i>
Date of change	14 July 2026
No. of securities held prior to change	A. 983,920 B. 2,000,000 C. 2,000,000 D. 2,000,000 E. 2,926,433 F. 21,389

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	A. Fully paid ordinary shares B. Unlisted options @\$0.20 Exp 14/12/2026 C. Unlisted options @\$0.20 Exp 11/07/2026 D. Unlisted options @\$0.15 Exp 03/06/2027 E. Share Rights in lieu of director fees F. Unlisted options @\$0.042 Exp 23 Dec 2027
Number acquired	A. Nil B. Nil C. Nil D. Nil E. 2,641,477 F. Nil
Number disposed	A. Nil B. Nil C. 2,000,000 D. Nil E. Nil F. Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	A. N/A B. N/A C. Nil D. N/A E. Deemed price of \$0.016 per right F. N/A
Number disposed	A. N/A B. N/A C. Nil D. N/A E. N/A F. N/A
No. of securities held after change	A. 983,920 B. 2,000,000 C. Nil D. 2,000,000 E. 5,567,910 F. 21,389
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	A. N/A B. N/A C. Lapse of unlisted options D. N/A E. Issue of Share Rights in lieu of Director fees for the period 1 Jan26 to 30 Jun26 pursuant to shareholder approval at the AGM held 29 May 2026. F. N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.